Monthly Horizon Scanning Report – August 2026
Monthly horizon scanning reports are designed to inform the NHS about new products, significant changes to product licences, significant new guidance, and decisions that have been made by recognised bodies.
This edition covers new and updated medicines and guidance published in July 2026.
This information is produced for use by NHS healthcare professionals.
Adalimumab, infliximab, and ustekinumab in pyoderma gangrenosum
RDTC D&T reviews are prepared in response to specific requests. They are intended for use by drug and therapeutics groups or equivalent committees, to support the review of applications to use a treatment in an individual or cohort. They are not intended to be used as standalone publications
A copy of this review is available on request from nuth.nyrdtc.rxsupp@nhs.net.
Monthly formulary amendments – August 2025
Monthly Formulary Amendments Documents list any NICE Technology Appraisals, NICE Guidelines, MHRA Drug Safety Updates, and National Patient Safety Alerts published in the previous calendar month which may have an impact on local formularies and guidelines. This document is for APCs, and formulary committees to ensure formularies remain up to date, and in line with latest NICE guidance and safety information.
This edition covers guidance and alerts published in August 2025.
It includes a suggested formulary position for APCs/formulary committees, together with a summary of any financial/commissioning implications. The purpose of the document is to support consistent decision making by APCs.
This information is produced for use by NHS healthcare professionals and RDTC stakeholders
Regional Prescribing Position North East and Yorkshire Region.
August update
The purpose of this bulletin is to provide the regional team with an overview of the prescribing position in the North East & Yorkshire region, the progress made in the National Medicines Optimisation Opportunities and the wider focus on prescribing for the North East and Yorkshire ICBs.
Monthly Horizon Scanning Report – August 2025
Monthly horizon scanning reports are designed to inform the NHS about new products, significant changes to product licenses, significant new guidance, and decisions that have been made by recognised bodies.
This information is produced for use by NHS healthcare professionals.
Formulary assessment – Budesonide 4mg suppositories
Formulary assessment tools are templates to support local decision making. They list NICE guidance, MHRA safety advice, and other relevant high quality advice and guidelines relevant to making decisions for local formularies.
The templates are pre-populated with useful information to reduce duplication of effort, with space for the addition of local information as appropriate. The purpose of the document is to support consistent decision making by formulary groups and APCs.
The information in this document is correct at the time of publication and formulations may change. This information is produced for use by NHS healthcare professionals and RDTC stakeholders.
Pylera for the eradication of Helicobacter Pylori infection
Overview
Medicines in Practice is a series of evidence–based publications specifically designed to support stakeholder medicines optimisation services. The series aims to maximise health gains through the optimum use of medicines, by influencing and changing prescribing behaviour.
Pylera is a new triple fixed-dose combination capsule containing bismuth, metronidazole and tetracycline. In combination with omeprazole, it is indicated for the eradication of H. pylori and prevention of relapse of peptic ulcers in patients with active or a history of H. pylori associated ulcers. The aim of this report is to evaluate the efficacy, safety and potential place in therapy of Pylera.
Monthly formulary amendments – August 2024
Monthly Formulary Amendments Documents list any NICE Technology Appraisals, NICE Guidelines, MHRA Drug Safety Updates, and National Patient Safety Alerts published in the previous calendar month which may have an impact on local formularies and guidelines. This document is for APCs, and formulary committees to ensure formularies remain up to date, and in line with latest NICE guidance and safety information.
This edition covers guidance and alerts published in August 2024.
It includes a suggested formulary position for APCs/formulary committees, together with a summary of any financial/commissioning implications. The purpose of the document is to support consistent decision making by APCs.
This information is produced for use by NHS healthcare professionals and RDTC stakeholders.
Disease-modifying therapies for Alzheimer’s disease
Overview
Evaluation reports aim to give objective information and guidance on medicines and medical devices to commissioners of health services, prescribers and others. They include efficacy, adverse effects, place in treatment and arrangements for prescribing.
A new generation of disease-modifying therapies (DMTs) for Alzheimer’s disease are in development and the potentially eligible population for these agents is very large. The aim of this evaluation report is to briefly discuss the effectiveness and safety of lecanemab and donanemab and attempt to estimate their potential impact on patients and services in the North of England.
Prescribing Update Newsletter – August 2024
Prescribing support newsletters aim to inform readers of work done by the unit and work in progress, to help tailor local work plans and highlight any ‘topical’ issues in prescribing or medicines management.
If you have any suggestions for future topics for the newsletter, then please contact nuth.nyrdtc.rxsupp@nhs.net
This month’s edition focuses on recent RDTC publications and the dates of our upcoming demo and Q&A sessions on RDTC reports, publications, and resources.
View the preview below on desktop, or click here to download a copy.